Transplant News and Research

RSS

New bill offers hope to HIV patients on transplant waiting lists

A bill scheduled to be signed into law today by President Obama reverses the longtime ban on letting HIV-infected people donate their organs for transplantation after death, a move that offers hope to thousands of HIV patients on transplant waiting lists.

22 Nov 2013

Attractants prevent maturing nerve cells from migrating into brain

A vision is to implant nerve precursor cells in the diseased brains of patients with Parkinson's and Huntington's diseases, whereby these cells are to assume the function of the cells that have died off.

21 Nov 2013

People who consume nuts daily are 20% less likely to die

In the largest study of its kind, people who ate a daily handful of nuts were 20 percent less likely to die from any cause over a 30-year period than were those who didn't consume nuts, say scientists from Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the Harvard School of Public Health.

21 Nov 2013

Researchers associate some insomnia symptoms with higher mortality risk in men

Insomnia, the most common sleep disorder, affects up to one-third of the population in the United States. In new findings, researchers from Brigham and Women's Hospital have found that some insomnia symptoms are associated with an increased risk of mortality in men.

20 Nov 2013

Once-daily edoxaban prevents stroke in patients with atrial fibrillation

According to the United States Centers for Disease Control and Prevention, over 800,000 Americans die each year from heart disease and stroke. Stroke is the leading cause of serious long-term disability and death in the US. In addition to lifestyle changes, medications such as anti-blood clotting drugs are helpful in the prevention of stroke.

20 Nov 2013

Heart failure patients receiving LVAD may benefit from injection of powerful cells directly into heart

A multicenter team of researchers within the NIH-funded Cardiothoracic Surgical Trials Network, led by Icahn School of Medicine at Mount Sinai, have found end-stage heart failure patients who receive a surgically implanted left ventricular assist device heart pump may also benefit from a single dose of millions of powerful cells injected directly into their heart during surgery.

19 Nov 2013

Study finds patients treated with varespladib drug more likely to experience cardiovascular events

Patients with acute coronary syndrome who were treated with the experimental drug varespladib were more likely to experience additional cardiovascular events - including sudden death, heart attack and stroke - than those treated with placebo, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

19 Nov 2013

Long-term use of PDE3 inhibitors can lead to increased risk for sudden cardiac death

Drugs known as PDE3 inhibitors save many lives by helping failing hearts do a better job of pumping blood. But those same medications come with a sometimes deadly cost when taken for long periods: an increased risk for sudden cardiac death.

19 Nov 2013

TOPCAT trial results of spironolactone presented at AHA Scientific Sessions

A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.

19 Nov 2013

Paragonix files second 510(k) with FDA for Sherpa Pak Cardiac Transport System

Paragonix Technologies, Inc. today announced that it has successfully completed filing of a second Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA) for its Paragonix Sherpa Pak Cardiac Transport System(CTS).

18 Nov 2013

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.

18 Nov 2013

Experts develop new working formulation for reporting of cardiac antibody-mediated rejection

Antibody-mediated rejection of the transplanted heart is a recognized clinical complication and a major limitation to survival of patients who have undergone heart transplantation. Experts have now developed a new working formulation for the pathologic diagnosis, grading, and reporting of cardiac antibody-mediated rejection.

18 Nov 2013

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

OPKO Health, Inc., has completed patient recruitment in the first phase 3 trial of Rayaldy to treat patients with secondary hyperparathyroidism, stage 3 or 4 chronic kidney disease and vitamin D insufficiency.

16 Nov 2013

Small molecule compound shows significant success in controlling polyomaviruses

A team of scientists reports that a small molecule compound showed significant success in controlling the infectivity and spread of three polyomaviruses in human cell cultures. To date there has been no medicine approved to treat such viruses, which prey on transplant recipients, people with HIV, and others whose immune systems have been weakened.

15 Nov 2013

Internal body clock may contribute to morning peak in heart attacks and ischemic strokes

Cardiovascular disease is the number one cause of death in both men and women, and most adverse cardiovascular events tend to happen in the morning. In new findings published in the November issue of Blood, researchers from Brigham and Women's Hospital (BWH) and Oregon Health & Science University have discovered that the internal body clock may contribute to the morning peak in heart attacks and ischemic strokes.

13 Nov 2013

Tailored doses of pre-transplant drug therapy in Glaucomatous patients boosts survival rates to over 90%

Chronic Granulomatous Disease is a rare immune deficiency that seriously compromises organ function and is life-threatening, with 20-30 per cent of patients dying within the first two decades of life.

13 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Transplant News and Research

New bill offers hope to HIV patients on transplant waiting lists

Attractants prevent maturing nerve cells from migrating into brain

People who consume nuts daily are 20% less likely to die

Researchers associate some insomnia symptoms with higher mortality risk in men

Once-daily edoxaban prevents stroke in patients with atrial fibrillation

Heart failure patients receiving LVAD may benefit from injection of powerful cells directly into heart

Study finds patients treated with varespladib drug more likely to experience cardiovascular events

Long-term use of PDE3 inhibitors can lead to increased risk for sudden cardiac death

TOPCAT trial results of spironolactone presented at AHA Scientific Sessions

Paragonix files second 510(k) with FDA for Sherpa Pak Cardiac Transport System

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Experts develop new working formulation for reporting of cardiac antibody-mediated rejection

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

Small molecule compound shows significant success in controlling polyomaviruses

Internal body clock may contribute to morning peak in heart attacks and ischemic strokes

Tailored doses of pre-transplant drug therapy in Glaucomatous patients boosts survival rates to over 90%

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Livers from donors with pre-hospital cardiac arrest considered for transplant

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News